Why are cancer clinical trials important?
By Mayo Clinic staff
Cancer clinical trials help physician-scientists at Mayo Clinic find new and better ways to control and treat cancer. They are also an important option for many people facing a difficult cancer diagnosis. Joining a trial may provide experimental, cutting-edge treatment options.
"We have over 300 cancer clinical trials every year that are testing new drugs and bringing treatments to patients," says Cheryl Willman, M.D., executive director of Mayo Clinic Cancer Programs, and director of the Mayo Clinic Cancer Center. "Cancer clinical trials are essential to advancing our knowledge in cancer care."
During a clinical trial, participants receive experimental treatments and researchers determine if those treatments are safe and effective. A clinical trial might study new cancer drugs or new combinations of drugs, new medical procedures, new surgical techniques or devices, new ways to use existing treatments, and even lifestyle or behavior changes.
For a new cancer treatment to become standard, it usually goes through two or three phases of a clinical trial. The early phases of cancer clinical trials are designed to study the safety of the new treatment. Later phases determine the effectiveness of the new treatment while continuing to study its safety.
For an explanation of how a clinical trial moves an experimental treatment from an idea to patient care, watch "The Clinical Trial Journey" video:
Learn more
Read FAQs about clinical trials and learn how clinical trials are helping patients with cancer.
For information about participating in cancer clinical trials at Mayo Clinic, contact:
Mayo Clinic Cancer Center
Clinical Trials Referral Office
855-776-0015
To have someone from the Mayo Clinic Cancer Center Clinical Trials Referral Office contact you, complete this contact form.
Related Posts
New Mayo Clinic research represents a promising step toward identifying biological signals or biomarkers that may aid in early detection.
Study results showed significantly higher survival rates when blinatumomab was added to chemotherapy for people with B-cell acute lymphoblastic leukemia.
Research shows screening protocols fail to catch a notable number of people carrying genetic mutations associated with increased cancer risk.